1. Executive Summary (Confidence: High)

Tolremo Therapeutics addresses one of the most critical challenges in oncology: the nearly universal emergence of drug resistance that leads to patient relapse. Founded in 2017 as a spin-off from ETH Zürich, the company pioneered the understanding of "transcriptional non-oncogene addiction"—a process where cancer cells shift their gene expression patterns to survive initial treatment without the immediate need for new genetic mutations. By identifying and targeting the early, reversible steps of resistance, Tolremo aims to make current cancer treatments work longer and more effectively.

The organization’s flagship asset, TT125-802, is a selective inhibitor of the CBP/p300 bromodomain, a master regulator of the gene expression changes that drive therapy evasion. Following a successful USD 39 million Series A round in 2023, the company has transitioned into clinical development, dosing the first patient in a Phase 1 trial in mid-2024. Tolremo's business strategy centers on "add-on" combination therapies, positioning its technology as a essential companion to blockbuster targeted drugs like KRAS and EGFR inhibitors in large-market indications such as lung, colorectal, and prostate cancer.